AssetMark Inc’s Immunovant IMVT Stock Holding History

AssetMark Inc’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.91K	Hold	117	–	–	﹤0.01%	2744
2025 Q4	$2.97K	Buy	117 +5	+4%	+$111	﹤0.01%	2649
2025 Q3	$1.8K	Sell	112 -21	-16%	-$340	﹤0.01%	2648
2025 Q2	$2.13K	Sell	133 -2,188	-94%	-$33.1K	﹤0.01%	2411
2025 Q1	$39.7K	Sell	2,321 -289	-11%	-$6.05K	﹤0.01%	1503
2024 Q4	$64.7K	Sell	2,610 -281	-10%	-$7.97K	﹤0.01%	1347
2024 Q3	$82.4K	Buy	2,891 +1,228	+74%	+$36.2K	﹤0.01%	1182
2024 Q2	$43.9K	Buy	1,663 +24	+1%	+$683	﹤0.01%	1260
2024 Q1	$53K	Buy	1,639 +182	+12%	+$6.64K	﹤0.01%	1152
2023 Q4	$61.4K	Buy	+1,457	New	+$53.6K	﹤0.01%	1119

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AssetMark Inc's IMVT Position: Q1 2026 in Review

AssetMark Inc held its Immunovant (IMVT) position steady in Q1 2026 at 117 shares worth $2.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

AssetMark Inc first reported a position in IMVT in Q4 2023 and has held it in 10 quarters since. The position peaked at $82.4K in Q3 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

AssetMark Inc held 117 shares of Immunovant worth $2.91K as of Q1 2026.
AssetMark Inc left its Immunovant share count unchanged in Q1 2026.
Immunovant made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #2744 holding.
AssetMark Inc first reported a position in Immunovant in Q4 2023 and has held it in 10 quarters since.
AssetMark Inc's Immunovant position peaked at $82.4K in Q3 2024.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.